Details:
The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Platform Product Type: Peptide
Partner/Sponsor/Collaborator: Fujitsu
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger November 12, 2020